1.Pharmacodynamic Substances and Mechanisms of Xinglou Chengqi Tang in Treating Post-stroke Complications: A Review
Yujin ZHANG ; Xiangzhuo LIU ; Zhouyang CHEN ; Zihao SONG ; Xinyi LIU ; Yizhi YAN ; Chaoya LI ; Yingyan FANG ; Shasha YANG ; Xueqin CHENG ; Zhou XIE ; Sijie TAN ; Peng ZENG ; Yue ZHANG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(1):327-337
Stroke is the leading cause of death and disability among adults in China, and its common complications include digestive system abnormalities, cognitive impairment, depression, stroke-associated pneumonia, and hemiplegia. The combination of traditional Chinese and Western medicine has great potential in treating post-stroke complications. Xinglou Chengqitang (XLCQT) is a representative prescription of alleviating the disease in the upper part by treating the lower part. It has definite therapeutic effect and high safety. Clinically, XLCQT is often used to treat stroke and its complications. However, the quantity and quality of clinical trials of XLCQT in treating post-stroke complications need to be improved. Additionally, since the basic research is weak, the material basis and multi-target mechanism for the efficacy of this prescription are unknown. This article reviews XLCQT in terms of the pharmacodynamic basis, medicinal properties, safety evaluation, and progress in clinical research and mechanisms in treating post-stroke complications. This article summarizes 22 key active ingredients of XLCQT in treating acute stroke complicated with syndrome of phlegm heat and fu-organ excess. Among these key active ingredients, resveratrol, kaempferol, luteolin, chrysoeriol, apigenin, (+)-catechin, and adenosine have good pharmacokinetic properties and high bioavailability. The mechanisms of XLCQT in treating post-stroke complications are complex, including inflammatory response, brain-gut axis, hypothalamic-pituitary-adrenal (HPA) axis, intestinal flora, neurotrophic factors, autophagy, oxidative stress, and free radical damage. This review helps to deeply understand the pharmacodynamic basis and mechanisms of XLCQT in treating post-stroke complications and provides a theoretical basis for the clinical application of XLCQT against post-stroke complications and the development of drugs.
2.Treating Vulnerable Atherosclerotic Plaque from the Perspective of "Abscess and Ulcer within the Vessels"
Yajie WANG ; Min WU ; Zihao ZHANG ; Zeping WANG ; Longtao LIU
Journal of Traditional Chinese Medicine 2026;67(12):1349-1352
The morphological characteristics and pathological progression of vulnerable plaques in atherosclerosis (AS) exhibit a high degree of similarity to the concept of "abscesses and ulcers" in traditional Chinese medicine (TCM). Therefore, vulnerable atherosclerotic plaques can be analogized as "abscesses and ulcers within the vessels", for which deficiency, stasis and toxin constitute the core pathogenesis. The pathological evolution progresses through three sequential stages, deficiency leading to pathological substances, with phlegm and stasis accumulating into a mass; the mass transforming into putridity, with internal decay and external thinning; putridity brewing toxin, and toxin accumulation threatening rupture, ultimately resulting in plaque instability. Accordingly, a stage-specific treatment strategy is established. In the early stage, it is suggested to supplement deficiency, resolve the mass, dissipate stasis, and prevent putridity, using Liujunzi Decoction (六君子汤) combined with Danshen Decoction (丹参饮) with modifications. In the middle stage, the treatment should focus on transforming putridity to generate new tissue, and rectifying healthy qi to consolidate the body, with modified Tuoli Xiaodu Powder (托里消毒散). In the late stage, the treatment principle is clearing and resolving putridity toxin, cooling the blood, and preventing ulcerative rupture, using modified Simiao Yong'an Decoction (四妙勇安汤) combined with Xijiao Dihuang Decoction (犀角地黄汤).
3.Expert consensus on the application of artificial intelligence in lung cancer screening, diagnosis, and treatment (2026 edition)
Wenzhao ZHONG ; Haibo WANG ; Yi HU ; Hao ZHANG ; Jigang DAI ; Junqiang FAN ; Guibin QIAO ; Fan YANG ; Jian HU ; Fengwei TAN ; Xuening YANG ; Qiang PU ; Zihao CHEN ; Hongxia TIAN ; Lunxu LIU ; Hecheng LI ; Xiaolong YAN ; Zongyang YU ; Zhenbin QIU ; Yihua SUN ; Jing HU ; Yuhang SHI ; Zhifei GUO ; Peng ZHANG ; Kezhong CHEN ; Shugeng GAO ; Yilong WU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(06):848-856
With the continuous deepening of the concept of precision diagnosis and treatment for lung cancer, how to achieve higher efficiency and accuracy in the screening, diagnosis, and treatment pathways in clinical practice has become an important issue that urgently needs to be overcome. The current clinical difficulty lies in the fact that despite continuous advancements in imaging and molecular diagnostic technologies, there are still limitations in manual efficiency and subjective experience when it comes to massive data analysis and multi-scale feature extraction. Artificial intelligence (AI), especially algorithm systems based on deep learning, is an innovative technology capable of deeply empowering medical big data. This method utilizes algorithms such as convolutional neural networks, combined with radiomics, pathomics, and multi-modal data fusion analysis, demonstrating immense potential in early precise detection and benign-malignant differentiation of pulmonary nodules, digital pathological subtype recognition and non-invasive prediction of driver genes, precise 3D surgical planning and automatic delineation of radiotherapy target volumes, as well as dynamic risk warning during follow-up. This innovative technology provides a brand-new solution for realizing intelligent and individualized lung cancer diagnosis and treatment models. This consensus, based on the latest evidence from evidence-based medicine and combined with the development trends in the AI field and real-world clinical needs, was ultimately formed by gathering the consensus opinions of multidisciplinary experts in radiology, pathology, thoracic surgery, and other fields. The main content covers the application specifications of AI in the three core scenarios of lung cancer screening, diagnosis, and treatment, the technical standards for data collection and algorithm validation, as well as the ethical and regulatory challenges faced at the current stage. It aims to clarify the applicable boundaries of AI as a clinical auxiliary decision support tool, providing scientific guidance and standardized exploration directions for peers currently engaged in or planning to carry out AI-assisted clinical diagnosis, treatment, and translation of lung cancer.
4.Research advances in applications of virtual reality in radiotherapy
Chinese Journal of Radiological Health 2026;35(2):272-278
Malignant tumors are a class of diseases that pose a serious threat to human health, and radiotherapy (RT) is one of the essential treatment modalities. Virtual reality (VR) technology, with its unique characteristics of immersion, interactivity, and imagination, demonstrates tremendous application potential in radiotherapy. Several randomized controlled trials have confirmed that VR, as a non-pharmacological intervention, can effectively alleviate anxiety in patients, especially children, and improve treatment adherence. In medical education and professional training, VR provides safe training platforms for radiation oncologists, medical physicists, and radiation therapists through the construction of high-fidelity virtual environments. These platforms can be used for training skills in target volume delineation, treatment plan evaluation, and equipment quality control, thereby significantly improving training efficiency and quality. Furthermore, VR technology enables three-dimensional visualization and intuitive evaluation of treatment plans, facilitates multidisciplinary team (MDT) collaboration, and provides new paradigms for the development of real-time guidance technologies that integrate with augmented reality. This article systematically reviews the current applications of VR technology in the clinical practice, medical education, radiation protection, and scientific research of radiotherapy. It also discusses future prospects for integrating VR with artificial intelligence (AI), augmented reality (AR), and haptic feedback technologies. This review provides a valuable reference for the standardized application of VR technology in radiotherapy and radiation protection in China.
5.Research advances in applications of virtual reality in radiotherapy
Chinese Journal of Radiological Health 2026;35(2):272-278
Malignant tumors are a class of diseases that pose a serious threat to human health, and radiotherapy (RT) is one of the essential treatment modalities. Virtual reality (VR) technology, with its unique characteristics of immersion, interactivity, and imagination, demonstrates tremendous application potential in radiotherapy. Several randomized controlled trials have confirmed that VR, as a non-pharmacological intervention, can effectively alleviate anxiety in patients, especially children, and improve treatment adherence. In medical education and professional training, VR provides safe training platforms for radiation oncologists, medical physicists, and radiation therapists through the construction of high-fidelity virtual environments. These platforms can be used for training skills in target volume delineation, treatment plan evaluation, and equipment quality control, thereby significantly improving training efficiency and quality. Furthermore, VR technology enables three-dimensional visualization and intuitive evaluation of treatment plans, facilitates multidisciplinary team (MDT) collaboration, and provides new paradigms for the development of real-time guidance technologies that integrate with augmented reality. This article systematically reviews the current applications of VR technology in the clinical practice, medical education, radiation protection, and scientific research of radiotherapy. It also discusses future prospects for integrating VR with artificial intelligence (AI), augmented reality (AR), and haptic feedback technologies. This review provides a valuable reference for the standardized application of VR technology in radiotherapy and radiation protection in China.
6.Research advances in applications of virtual reality in radiotherapy
Chinese Journal of Radiological Health 2026;35(2):272-278
Malignant tumors are a class of diseases that pose a serious threat to human health, and radiotherapy (RT) is one of the essential treatment modalities. Virtual reality (VR) technology, with its unique characteristics of immersion, interactivity, and imagination, demonstrates tremendous application potential in radiotherapy. Several randomized controlled trials have confirmed that VR, as a non-pharmacological intervention, can effectively alleviate anxiety in patients, especially children, and improve treatment adherence. In medical education and professional training, VR provides safe training platforms for radiation oncologists, medical physicists, and radiation therapists through the construction of high-fidelity virtual environments. These platforms can be used for training skills in target volume delineation, treatment plan evaluation, and equipment quality control, thereby significantly improving training efficiency and quality. Furthermore, VR technology enables three-dimensional visualization and intuitive evaluation of treatment plans, facilitates multidisciplinary team (MDT) collaboration, and provides new paradigms for the development of real-time guidance technologies that integrate with augmented reality. This article systematically reviews the current applications of VR technology in the clinical practice, medical education, radiation protection, and scientific research of radiotherapy. It also discusses future prospects for integrating VR with artificial intelligence (AI), augmented reality (AR), and haptic feedback technologies. This review provides a valuable reference for the standardized application of VR technology in radiotherapy and radiation protection in China.
7.Evaluation of antimicrobial activity of milk exosomes loaded with rifamycin S derivative
Zhanqun YANG ; Xiang LI ; Chenghua LIU ; Mengzhu ZHENG ; Shiyong FAN ; Yuchao DONG ; Zihao WANG ; Jian LIN ; Guang YANG ; Long CHEN
Chinese Journal of Pharmacology and Toxicology 2025;39(3):208-215
OBJECTIVE To design and synthesize rifamycin S derivatives and load them into milk exosomes to evaluate their in vitro antimicrobial activity.METHODS Rifamycin S derivatives were synthe-sized and characterized by mass spectrometry and NMR.Using the dilution assay method,the inhibitory activity of each rifamycin S derivatives molecule against Staphylococcus aureus and Pseudomonas aerugi-nosa was determined,and the IC50 was calculated.Derivatives molecules with excellent antimicrobial activity were selected and loaded into milk exosomes using the ultrasonication method,resulting in the preparation of milk exosome-loaded rifamycin S derivatives.The antimicrobial activity against Staphylo-coccus aureus was determined using the dilution assay method.The inhibitory effect of the exosome-loaded rifamycin S derivatives on Staphylococcus aureus residing within macrophages was detected using the plate colony counting method.RESULTS Three rifamycin S derivatives were successfully designed and synthesized,which demonstrated superior antimicrobial activity against Staphylococcus aureus(the parent compound's antimicrobial activity is merely from 1/20 to 1/80 of that of the three rifamycin S derivatives)and Pseudomonas aeruginosa(the parent compound's antimicrobial activity is only 1/14 and 1/9 of that of compound 1 and compound 3)compared to the parent compound.The loading of milk exosomes with the rifamycin S derivatives compound 3 was successfully achieved,with a loading efficiency of 10.9%.The antimicrobial activity of the compound after exosome loading was significantly enhanced against Staphylococcus aureus in vitro and against Staphylococcus aureus residing within macrophages(P<0.01).CONCLUSION The designed and synthesized derivatives of rifamycin S possess stronger anti-microbial activity,and their antibacterial efficacy against both extracellular and intracellular bacteria can be further enhanced after loading into exosomes.
8.Evaluation of antimicrobial activity of milk exosomes loaded with rifamycin S derivative
Zhanqun YANG ; Xiang LI ; Chenghua LIU ; Mengzhu ZHENG ; Shiyong FAN ; Yuchao DONG ; Zihao WANG ; Jian LIN ; Guang YANG ; Long CHEN
Chinese Journal of Pharmacology and Toxicology 2025;39(3):208-215
OBJECTIVE To design and synthesize rifamycin S derivatives and load them into milk exosomes to evaluate their in vitro antimicrobial activity.METHODS Rifamycin S derivatives were synthe-sized and characterized by mass spectrometry and NMR.Using the dilution assay method,the inhibitory activity of each rifamycin S derivatives molecule against Staphylococcus aureus and Pseudomonas aerugi-nosa was determined,and the IC50 was calculated.Derivatives molecules with excellent antimicrobial activity were selected and loaded into milk exosomes using the ultrasonication method,resulting in the preparation of milk exosome-loaded rifamycin S derivatives.The antimicrobial activity against Staphylo-coccus aureus was determined using the dilution assay method.The inhibitory effect of the exosome-loaded rifamycin S derivatives on Staphylococcus aureus residing within macrophages was detected using the plate colony counting method.RESULTS Three rifamycin S derivatives were successfully designed and synthesized,which demonstrated superior antimicrobial activity against Staphylococcus aureus(the parent compound's antimicrobial activity is merely from 1/20 to 1/80 of that of the three rifamycin S derivatives)and Pseudomonas aeruginosa(the parent compound's antimicrobial activity is only 1/14 and 1/9 of that of compound 1 and compound 3)compared to the parent compound.The loading of milk exosomes with the rifamycin S derivatives compound 3 was successfully achieved,with a loading efficiency of 10.9%.The antimicrobial activity of the compound after exosome loading was significantly enhanced against Staphylococcus aureus in vitro and against Staphylococcus aureus residing within macrophages(P<0.01).CONCLUSION The designed and synthesized derivatives of rifamycin S possess stronger anti-microbial activity,and their antibacterial efficacy against both extracellular and intracellular bacteria can be further enhanced after loading into exosomes.
9.Research progress on epidemiology,pathogenesis and treatment of keratoco-nus
Recent Advances in Ophthalmology 2025;45(7):571-577
Keratoconus is a progressive eye disease that primarily affects individuals in adolescence and early adult-hood.Dilating changes in the cornea cause it to thin and become steeper,resulting in irregular astigmatism and decreased vision.Keratoconus has multiple etiologies and pathogenic factors,including genetic,environmental,biomechanical and cellular factors.Environmental factors encompass eye rubbing,UV exposure,and wearing contact lenses.At the cellular level,the interaction of complex factors such as hormonal changes,extracellular enzyme activity,and changes in biochemi-cal and biomechanical signaling pathways disrupts collagen crosslinking within the stroma,leading to the loss and distortion of the integrity of normal corneal anatomical structures.Detection of keratoconus in its early stages remains a challenge,and corneal topographic maps are the primary diagnostic tool for keratoconus.However,in early cases,the use of a single parameter to diagnose keratoconus is not sufficient.In addition to corneal topographic maps,corneal thickness measure-ments and high-order aberration data are now commonly used detection methods.Clinically,keratoconus is diagnosed by clinical examination and corneal imaging.Advanced imaging platforms can improve the detection rate of keratoconus,facil-itating early diagnosis and monitoring of disease progression.Treatment strategies for keratoconus are tailored to the severi-ty and progression of the disease.In the early stages,glasses or soft contact lenses for vision correction are sufficient.As the disease progresses,rigid breathable contact lenses or scleral contact lenses may be needed.Corneal crosslinking has emerged as a key treatment aimed at stopping the progression of corneal dilation.The epidemiology,pathogenesis and treatment of keratoconus will be comprehensively reviewed in this paper.
10.Progress in the pharmacological effects of naringin on cardiovascular diseases
Dan LIU ; Jiawei MIAO ; Zihao TAN ; Chunyao HE ; Mingzhu ZHAO ; Xiuzhen HE
Chinese Journal of Clinical Pharmacology and Therapeutics 2025;30(2):272-281
Naringin is a flavonoid compound with a wide range of biological and pharmacologi-cal activities,which can be used in treating tumor,diabetes,neurodegenerative diseases,cardiovascu-lar diseases,metabolic syndrome,etc.Among them,the application of naringin in cardiovascular diseases has attracted the attention of many re-searchers.This article mainly reviews the role of naringin in cardiovascular disease(regulating blood lipids,anti atherosclerosis,lowering blood pres-sure,inhibiting myocardial hypertrophy,anti myo-cardial infarction,protecting myocardial ischemia/reperfusion injury,reducing myocardial ischemia/reperfusion injury and improving pulmonary arteri-al hypertension),the protective effect on cardiotox-icity,and the signal pathways in cardiovascular dis-ease(PI3K-Akt-mTOR,p-eNOS/p-Akt/p-ERK,miR-126/GSK-3 β/β-Catenin),clinical trials,etc.This pa-per is expected to review the current research sta-tus of naringin in cells and animal models so as to reveal its clinical application prospects and provide reference for further research in related fields.

Result Analysis
Print
Save
E-mail